期刊
ONCOTARGET
卷 8, 期 53, 页码 91085-91098出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.19555
关键词
clear cell renal cell carcinoma; nephrotoxin; anti-carcinogenic treatment; apoptosis; necrosis
资金
- Swedish Medical Research Council [9898, 14764]
- Swedish Cancer foundation
- Inga-Britt and Arne Lundberg Research Foundation
- John and Brit Wennerstrom Research Foundation
- Sahlgrenska University Hospital Grant LUA/ALF
Renal cell carcinoma (RCC), arising from the proximal tubule in the kidney, accounts for approximately 85% of kidney cancers and causes over 140,000 annual deaths worldwide. In the last decade, several new therapies have been identified for treatment of metastatic RCC. Although these therapies increase survival time compared to standard care, none of them has curative properties. The nephrotoxin orellanine specifically targets proximal tubular epithelial cells, leaving other organs unaffected. We therefore hypothesized that the selective toxicity of orellanine extends to clear cell RCC (ccRCC) cells since they emanate from proximal tubular cells. Orellanine would thus target both primary and metastatic ccRCC in vitro and in vivo. We found that orellanine induces dose-dependent cell death in proximal tubular cells and in all ccRCC cells tested, both primary and cell lines, with no toxicity detected in control cells. The toxic action of orellanine involve decreased protein synthesis, disrupted cell metabolism and induction of apoptosis. In nude rats carrying human ccRCC xenografts, brief orellanine treatment eliminated more than 90% of viable tumor mass compared to control rats. This identifies orellanine as a potential treatment concept for ccRCC patients on dialysis, due to its unique selective toxicity towards ccRCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据